Rigel Pharmaceuticals, Inc. (RIGL) Balance Sheet

NASDAQ: RIGLAssets, liabilities, debt and equity over 10 years.

RIGL balance sheet, 2025

December 31, 2025 · U.S. dollars

$513.6M assets = $122.1M liabilities + $391.5M equity

What it owns$513.6MCash & ST investments: $155.0M (30.2%)Cash & ST investments$155.0M · 30%Receivables: $51.8M (10.1%)Receivables $51.8MInventory: $11.5M (2.2%)Other current: $21.9M (4.3%)PP&E: $920,000 (0.2%)Goodwill & intangibles: $24.7M (4.8%)Other non-current: $247.8M (48.2%)Other non-current$247.8M · 48%=How it is financed$513.6MCurrent liabilities: $99.2M (19.3%)Current liabilities$99.2M · 19%Long-term debt: $22.5M (4.4%)Other LT liabilities: $395,000 (0.1%)Shareholders’ equity: $391.5M (76.2%)Shareholders’ equity$391.5M · 76%

Both columns are drawn to the same scale: what RIGL owns equals what it owes plus shareholders’ equity. Hover a block for its value.

RIGL financial health

Current ratio2.42
Comfortable · current assets cover current liabilities 2.42×
Debt / equity0.14
Low leverage · $0.14 of debt for each $1 of equity
Equity / assets76.2%
Equity-funded · of assets funded by shareholders
Cash / debt290.7%
Cash covers debt · cash & short-term investments vs total debt
Goodwill & intangibles4.8%
Mostly tangible · of total assets

Descriptive bands, not a rating. Fiscal 2025.

RIGL balance sheet trends, 2016–2025

Rigel Pharmaceuticals, Inc. balance sheet trends
MetricTrendThenLatestChange
Total assets$78.1M2016$513.6M2025+23.3%/yr
Total liabilities$23.1M2016$122.1M2025+20.3%/yr
Shareholders’ equity$55.0M2016$391.5M2025+24.4%/yr
Cash & short-term investments$74.8M2016$155.0M2025+8.4%/yr
Total debt$3.5M2016$53.3M2025+35.5%/yr
Net cash (debt)$71.3M2016$101.7M2025+$30.3M
Working capital$53.6M2016$140.9M2025+$87.3M
Book value per share$5.832016$20.782025+15.2%/yr
Current ratio3.3720162.422025−0.95
Debt / equity0.0620160.142025+0.07
Shares outstanding9.4M201618.8M2025+8.0%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

RIGL assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

RIGL liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

RIGL debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

RIGL balance sheet

Rigel Pharmaceuticals, Inc. annual balance sheet
2025202420232022202120202019201820172016
Assets
Cash & short-term investments$155.0M$77.3M$56.9M$58.2M$125.0M$57.3M$98.1M$128.5M$115.8M$74.8M
Cash & equivalents$40.6M$56.7M$32.8M$24.5M$18.9M$30.4M$22.5M$76.3M$38.3M$17.6M
Short-term investments$114.4M$20.6M$24.1M$33.7M$106.1M$27.0M$75.6M$52.2M$77.5M$57.1M
Receivables$51.8M$41.6M$30.6M$40.3M$15.5M$16.0M$10.1M$4.1M$0$0
Inventory$11.5M$6.0M$5.5M$9.1M$6.6M$1.6M$1.4M$894,000$0$0
Other current assets$21.9M$10.2M$6.3M$8.3M$7.4M$14.0M$9.5M$3.5M$1.7M$1.4M
Total current assets$240.2M$135.1M$99.3M$115.9M$154.5M$89.0M$119.0M$137.0M$117.4M$76.2M
Property, plant & equipment (net)$920,000$338,000$1.0M$2.8M$11.9M$20.6M$27.9M$1.4M$875,000$1.2M
Goodwill & intangible assets$24.7M$27.1M$13.9M$14.9M$0$0$0$0$0$0
Long-term investments$0$0$0$0$0$0$0$0$0$0
Other non-current assets$247.8M$1.4M$3.1M$640,000$974,000$824,000$696,000$735,000$803,000$764,000
Total assets$513.6M$164.0M$117.2M$134.3M$167.3M$110.4M$147.6M$139.1M$119.1M$78.1M
Liabilities
Accounts payable$7.2M$3.3M$7.1M$22.5M$3.8M$3.7M$4.2M$6.4M$2.6M$5.6M
Short-term debt$30.4M$7.6M$7.9M$1.1M$9.9M$8.6M$7.3M—$284,000$3.2M
Deferred revenue$1.4M$27.8M$17.0M$13.5M$10.5M$3.0M$25.3M$1.0M−$284,000−$3.2M
Total current liabilities$99.2M$63.3M$53.3M$65.2M$63.6M$40.8M$58.2M$27.7M$18.3M$22.6M
Long-term debt$22.5M$52.4M$52.4M$39.4M$19.9M$19.8M$9.8M$0$0$0
Lease obligations$1.0M$285,000$977,000$2.1M$10.7M$19.3M$26.5M———
Other long-term liabilities$395,000$45.0M$40.2M$43.2M$53.5M$15.7M$25.7M$1.5M$128,000$519,000
Total liabilities$122.1M$160.7M$145.9M$147.9M$137.0M$76.4M$93.8M$29.2M$18.5M$23.1M
Shareholders' equity
Common stock & paid-in capital$18,000$18,000$17,000$174,000$172,000$169,000$168,000$167,000$147,000$100,000
Retained earnings (deficit)−$1.02B−$1.39B−$1.41B−$1.38B−$1.32B−$1.31B−$1.28B−$1.21B−$1.14B−$1.06B
Treasury stock————————$0$0
Accumulated other comprehensive income$181,000$10,000$8,000−$153,000−$102,000−$4,000$23,000−$24,000−$82,000−$18,000
Minority interest————————$0$0
Total shareholders' equity$391.5M$3.3M−$28.6M−$13.6M$30.4M$34.0M$53.8M$109.9M$100.6M$55.0M
Key figures
Total debt$53.3M$60.0M$60.6M$41.6M$30.6M$39.1M$36.3M—$284,000$3.5M
Net cash (debt)$101.7M$17.4M−$3.6M$16.7M$94.4M$18.2M$61.8M—$115.5M$71.3M
Working capital$140.9M$71.8M$46.0M$50.7M$90.9M$48.1M$60.8M$109.3M$99.1M$53.6M
Tangible book value$366.7M−$23.8M−$42.5M−$28.6M$30.4M$34.0M$53.8M$109.9M$100.6M$55.0M
Book value per share$20.78$0.19−$1.65−$0.79$1.78$2.02$3.21$6.84$7.97$5.83
Shares outstanding18.8M17.7M17.4M17.2M17.0M16.9M16.7M16.1M12.6M9.4M
Current ratio2.422.131.861.782.432.182.044.946.403.37
Quick ratio2.081.881.641.512.211.791.864.786.313.31
Debt / equity0.1418.24——1.011.150.67—0.000.06
Equity / assets76.2%2.0%−24.4%−10.1%18.2%30.8%36.5%79.0%84.5%70.4%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 3, 2026); data from EODHD.

RIGL financial position

At the end of fiscal 2025 (December 31, 2025), Rigel Pharmaceuticals had total assets of $513.6 million (up 213.2% from a year earlier), total liabilities of $122.1 million and shareholders' equity of $391.5 million. It held $155.0 million in cash and short-term investments against $53.3 million of debt, a net cash position of $101.7 million. Its current ratio was 2.42. In the latest quarter (ended June 30, 2026) total assets were $521.1 million and equity $425.4 million.

Related: RIGL income statement, RIGL cash flow statement, RIGL key metrics. See the RIGL stock overview for the latest quote and news.

RIGL balance sheet FAQ

What are Rigel Pharmaceuticals's total assets?

Rigel Pharmaceuticals reported total assets of $513.6 million at the end of fiscal 2025 (December 31, 2025), compared with $164.0 million a year earlier.

How much debt does Rigel Pharmaceuticals have?

Rigel Pharmaceuticals had $53.3 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.14.

How much cash does Rigel Pharmaceuticals have?

Rigel Pharmaceuticals held $155.0 million in cash and short-term investments at the end of fiscal 2025; with $53.3 million of debt that is net cash of $101.7 million.

What is Rigel Pharmaceuticals's book value?

Rigel Pharmaceuticals's shareholders' equity (book value) was $391.5 million at the end of fiscal 2025, or $20.78 per share.

What is Rigel Pharmaceuticals's current ratio?

Rigel Pharmaceuticals had current assets of $240.2 million and current liabilities of $99.2 million, a current ratio of 2.42 (it can cover its short-term obligations).

How much goodwill does Rigel Pharmaceuticals have?

Rigel Pharmaceuticals carried $24.7 million of goodwill and intangible assets, 4.8% of total assets, at the end of fiscal 2025.

Biotechnology: balance sheet